Cargando…

Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia

CONTEXT: 11β-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia. Untreated, this enzyme deficiency leads to virilization, hypertension, and significant height impairment. PATIENT: We describe a patient from abroad who first presented to us at age 7 years for foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Nour, Munier A, Pacaud, Danièle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432823/
https://www.ncbi.nlm.nih.gov/pubmed/25983757
http://dx.doi.org/10.1186/s13633-015-0008-0
_version_ 1782371541511569408
author Nour, Munier A
Pacaud, Danièle
author_facet Nour, Munier A
Pacaud, Danièle
author_sort Nour, Munier A
collection PubMed
description CONTEXT: 11β-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia. Untreated, this enzyme deficiency leads to virilization, hypertension, and significant height impairment. PATIENT: We describe a patient from abroad who first presented to us at age 7 years for follow-up of ambiguous genitalia. He had been investigated and treated in Pakistan at 3-years-of-age following presentation for bilateral cryptorchidism. He was found to have 46, XX karyotype, elevated 17-OH progesterone and was diagnosed with congenital adrenal hyperplasia. In Pakistan, the patient had abdominal hysterectomy, bilateral salpingoophrectomy, and was started on corticosteroid replacement. At 7 years, shortly after immigrating to Canada, height was 138 cm and BMI 19.3 kg/m(2) (+2.9 SDS and +1.7 SDS, respectively, male growth chart) and blood pressure was greater than the 99th percentile for age and height. The patient had Prader stage III - IV genital anatomy. Bone age was significantly advanced, yielding a severely compromised predicted final adult height. Biochemical evaluation was consistent with 11β-hydroxylase deficiency congenital adrenal hyperplasia. INTERVENTION AND OUTCOME: In an attempt to improve final height, in addition to glucocorticoid replacement, this patient was treated with recombinant growth hormone and a third generation aromatase inhibitor (Letrozole) with an improvement in final height attained as compared with predicted height. CONCLUSIONS: This case of a 46,XX patient raised as male with congenital adrenal hyperplasia due to 11β-hydroxylase deficiency highlights a number of unique and difficult treatment challenges; specifically, the role of new therapeutic options for optimization of growth in the context of prior suboptimal disease management.
format Online
Article
Text
id pubmed-4432823
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44328232015-05-16 Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia Nour, Munier A Pacaud, Danièle Int J Pediatr Endocrinol Case Report CONTEXT: 11β-hydroxylase deficiency is the second most common form of congenital adrenal hyperplasia. Untreated, this enzyme deficiency leads to virilization, hypertension, and significant height impairment. PATIENT: We describe a patient from abroad who first presented to us at age 7 years for follow-up of ambiguous genitalia. He had been investigated and treated in Pakistan at 3-years-of-age following presentation for bilateral cryptorchidism. He was found to have 46, XX karyotype, elevated 17-OH progesterone and was diagnosed with congenital adrenal hyperplasia. In Pakistan, the patient had abdominal hysterectomy, bilateral salpingoophrectomy, and was started on corticosteroid replacement. At 7 years, shortly after immigrating to Canada, height was 138 cm and BMI 19.3 kg/m(2) (+2.9 SDS and +1.7 SDS, respectively, male growth chart) and blood pressure was greater than the 99th percentile for age and height. The patient had Prader stage III - IV genital anatomy. Bone age was significantly advanced, yielding a severely compromised predicted final adult height. Biochemical evaluation was consistent with 11β-hydroxylase deficiency congenital adrenal hyperplasia. INTERVENTION AND OUTCOME: In an attempt to improve final height, in addition to glucocorticoid replacement, this patient was treated with recombinant growth hormone and a third generation aromatase inhibitor (Letrozole) with an improvement in final height attained as compared with predicted height. CONCLUSIONS: This case of a 46,XX patient raised as male with congenital adrenal hyperplasia due to 11β-hydroxylase deficiency highlights a number of unique and difficult treatment challenges; specifically, the role of new therapeutic options for optimization of growth in the context of prior suboptimal disease management. BioMed Central 2015-05-15 2015 /pmc/articles/PMC4432823/ /pubmed/25983757 http://dx.doi.org/10.1186/s13633-015-0008-0 Text en © Nour and Pacaud; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Nour, Munier A
Pacaud, Danièle
Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
title Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
title_full Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
title_fullStr Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
title_full_unstemmed Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
title_short Height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
title_sort height augmentation in 11β-hydroxylase deficiency congenital adrenal hyperplasia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432823/
https://www.ncbi.nlm.nih.gov/pubmed/25983757
http://dx.doi.org/10.1186/s13633-015-0008-0
work_keys_str_mv AT nourmuniera heightaugmentationin11bhydroxylasedeficiencycongenitaladrenalhyperplasia
AT pacauddaniele heightaugmentationin11bhydroxylasedeficiencycongenitaladrenalhyperplasia